[
    {
        "file_name": "etonpharmaceuticalsinc_20191114_10-q_ex-10.1_11893941_ex-10.1_development agreement.pdf",
        "perturbation": [
            {
                "type": "Misaligned Terminology - In Text Contradiction",
                "original_text": "1.31 “Product” or “Products” means a product or products set forth in Exhibit A for Marketing by or for ETON in the Territory (and covered or intended to be covered by a Dossier) and manufactured and supplied by Aucta (or a Third Party as permitted by this Agreement) to ETON in fully packaged and labeled form and ready for commercialization by ETON.",
                "changed_text": "1.31 “Product” or “Products” means a product or products set forth in Exhibit A for Marketing by or for ETON in the Territory (and covered or intended to be covered by a Dossier) and manufactured and supplied by Aucta (or a Third Party as permitted by this Agreement) to ETON in fully packaged and labeled form and ready for commercialization by ETON.\n\n4.5 'Goods' shall refer to any tangible personal property related to marketing.",
                "explanation": "The contract defines 'Product' in Section 1.31 and then introduces 'Goods' in a completely different section (4.5) without clarifying if they are the same. This creates potential confusion about whether all provisions relating to 'Products' also apply to 'Goods.'",
                "location": "Section 1.31 and newly created Section 4.5"
            },
            {
                "type": "Misaligned Terminology - In Text Contradiction",
                "original_text": "1.26 “Net Sales” means, with respect to each Product sold in the Territory, the aggregate gross sales amount invoiced by ETON or any sublicensee or other party authorized by ETON to wholesale or distribute the Products on an arms-length basis to Third Parties in the Territory (“Gross Sales”), less (as applicable) the following ETON expenses as accrued and adjusted for amounts actually taken, consistent with ETON’S standard accounting practices in accordance with GAAP: (a) amounts refunded or credited for returned, damaged, outdated, short-dated or defective goods, and bad debts, and (b) all of the following: (i) taxes, duties and other governmental charges related to the production, use or sale of the Products (including, including without limitation the brand manufacturer’s tax imposed pursuant to the Patient Protection and Affordable\nCare Act (Pub. L. No. 111-148) as amended or replaced, but not including taxes assessed against the income derived from such sale); (ii) trade,\nquantity and cash discounts, allowances, retroactive price adjustments, credit incentive payments, chargebacks, patient support programs, and\nrebates (including governmental rebates or other price reductions provided, based on sales by ETON to any Governmental Entity or regulatory\nauthority in respect of state or federal Medicare, Medicaid, government pricing or similar programs;); and (iii) any costs incurred in connection with\nor arising out of compliance with any Risk Evaluation and Mitigation Strategies approved by the FDA and (iv) any expenses associated with\nserialization of the Products. Distribution of Licensed Products for clinical trials or as samples will not be deemed a “Net Sale” under this definition.",
                "changed_text": "1.26 “Net Sales” means, with respect to each Product sold in the Territory, the aggregate gross sales amount invoiced by ETON or any sublicensee or other party authorized by ETON to wholesale or distribute the Products on an arms-length basis to Third Parties in the Territory (“Gross Sales”), less (as applicable) the following ETON expenses as accrued and adjusted for amounts actually taken, consistent with ETON’S standard accounting practices in accordance with GAAP: (a) amounts refunded or credited for returned, damaged, outdated, short-dated or defective goods, and bad debts, and (b) all of the following: (i) taxes, duties and other governmental charges related to the production, use or sale of the Products (including, including without limitation the brand manufacturer’s tax imposed pursuant to the Patient Protection and Affordable\nCare Act (Pub. L. No. 111-148) as amended or replaced, but not including taxes assessed against the income derived from such sale); (ii) trade,\nquantity and cash discounts, allowances, retroactive price adjustments, credit incentive payments, chargebacks, patient support programs, and\nrebates (including governmental rebates or other price reductions provided, based on sales by ETON to any Governmental Entity or regulatory\nauthority in respect of state or federal Medicare, Medicaid, government pricing or similar programs;); and (iii) any costs incurred in connection with\nor arising out of compliance with any Risk Evaluation and Mitigation Strategies approved by the FDA and (iv) any expenses associated with\nserialization of the Products. Distribution of Products for clinical trials or as samples will not be deemed a “Net Sale” under this definition.\n\nIn calculating \"Net Revenue\", distribution of Licensed Articles for clinical trials or as samples will not be deemed a \"Net Revenue\".",
                "explanation": "The contract defines 'Net Sales' in Section 1.26. The added text introduces 'Net Revenue' and 'Licensed Articles' in Section 1.26 (end of section) without clarifying if they are the same or related. This creates potential confusion about calculating revenue and if clinical trials are included for 'Licensed Articles'.",
                "location": "Section 1.26"
            },
            {
                "type": "Misaligned Terminology - In Text Contradiction",
                "original_text": "3.4 Medical Inquires, Product Complaints and Recalls. ETON, Aucta and a designated third-party contract manufacturer shall share in the\nresponsibility for responding to any medical inquiries or complaints about any Products or addressing any circumstances that may result in a\npotential recall, market withdrawal, inventory retrieval, or similar action (“Recall Event”) as set forth in the Pharmacovigilance Agreement attached\nhereto as Exhibit B (the “Pharmacovigilance Agreement”) and to be entered into by the Parties and the contract manufacturer as soon as\npracticable.",
                "changed_text": "3.4 Medical Inquires, Product Complaints and Recalls. ETON, Aucta and a designated third-party contract manufacturer shall share in the\nresponsibility for responding to any medical inquiries or complaints about any Products or addressing any circumstances that may result in a\npotential recall, market withdrawal, inventory retrieval, or similar action (“Recall Event”) as set forth in the Pharmacovigilance Agreement attached\nhereto as Exhibit B (the “Pharmacovigilance Agreement”) and to be entered into by the Parties and the contract manufacturer as soon as\npracticable.\n\n15.12. Handling customer requests: The distributor will be fully responsible for processing client requests.",
                "explanation": "The contract defines how product complaints are handled in Section 3.4, but suddenly section 15.12 introduces a 'distributor' that will be fully responsible for processing client requests. It is not made clear whether the 'distributor' is Aucta, ETON, or another party, which could lead to confusion about who is responsible for handling customer requests and product complaints.",
                "location": "Section 3.4 and newly created Section 15.12"
            }
        ]
    }
]